TNIB News Alert Tni Biotech Inc (TNIB) 0.1305 10/15/2014 13:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tni Biotech Inc (TNIB) 0.1305 $TNIB

TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend
PR Newswire - Mon Sep 29, 2:27PM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company" , a biotechnology company pioneering the manufacturing both US and Internationally as well as the marketing of innovative therapies for cancer, HIV/AIDS, opportunistic infections and autoimmune diseases in emerging nations, issued a letter to its shareholders from CEO Noreen Griffin The letter follows:

TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible
PR Newswire - Tue Sep 23, 1:31PM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company" , a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced that the Depository Trust Company ("DTC" has approved our common stock for DTC's Deposit and Withdrawal at Custodian ("DWAC" service using a Fast Automated Securities Transfer Service ("FAST" transfer agent as the distribution point. The Company's shareholders holding their securities in street name can now transfer their shares electronically after buying or selling on the open market without the extra expense and delay resulting from the redundant process of requesting and transferring physical certificates.

TNI BioTech Announces Results of Annual Shareholders Meeting
PR Newswire - Tue Sep 09, 5:15AM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company" , a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced the results of its 2014 annual general meeting of shareholders.

TNI BioTech Inc. Announces First Shipment of Lodonal® to The Republic of Panama and The Republic of Malawi
PR Newswire - Wed Aug 27, 6:09AM CDT
TNI BioTech Inc. (OTCQB: TNIB), ("we" or the "Company" a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced it had received payment and will make its first shipments of Lodonal® to the Republic of Panama and The Republic of Malawi in conjunction with our marketing partner, The Brewer Group, Inc.

TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014
PR Newswire - Mon Aug 18, 9:25AM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company" a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today that the Company is providing a second notice of TNI BioTech's annual meeting of September 4, 2014.

TNI BioTech, Inc., Announces an Extension to the Record Date of its wholly owned subsidiary, Cytocom Inc., and Dividend now Set for September 30, 2014
PR Newswire - Thu Aug 14, 12:39PM CDT
TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company" a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today that the Company is extending the record date of the dividend of Cytocom Inc., shares to all shareholders of the Company to September 30th, 2014.

TNI BioTech and Hubei Qianjiang Pharmaceutical Co., Ltd Supplemental Collaborative Agreement
PR Newswire - Wed Aug 13, 7:08AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company" a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, announced today the signing of a supplemental agreement with Hubei Qianjiang Pharmaceutical Co., Ltd (SHSE:600568) ( Qianjiang) China on behalf of Cytocom, TNI BioTech's wholly owed subsidiary. The signing of the supplemental agreement accelerates clinical trial development in both America and China, for IRT-101 ("MENK" . In the hope of moving clinical development forward the parties agreed to the following:

TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card
PR Newswire - Mon Jul 28, 8:00AM CDT
TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or the "Company" , a biopharmaceutical company focused on the development, marketing and distribution of opioid-related immunotherapies, announced today that it has filed definitive proxy materials with the Securities and Exchange Commission in connection with its 2014 Annual Meeting of Shareholders to be held on Thursday, September 4, 2014, at 10 a.m., East Standard Time. The record date for determining those shareholders eligible to receive notice of, and to vote at, the 2014 Annual Meeting was set as of July 15, 2014.

TNI BioTech, Inc. Establishes New Record Date for Spin-Off Stock Dividend of Cytocom, Inc. Shares
PR Newswire - Mon Jul 14, 2:17PM CDT
TNI BioTech, Inc. - (OTCQB: TNIB) ("TNIB" or the "Company" , a biotechnology company focused on developing innovative, targeted immune therapies, today announced that its Board of Directors has extended the record date of our spin-off of Cytocom, Inc., a subsidiary of TNIB.

TNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal(TM) for Cancer and Receives First Sale in Africa - CORRECTION
PR Newswire - Wed Jun 25, 10:17AM CDT
TNI BioTech, Inc. (OTC-TNIB) ("TNI BioTech" earlier today announced that its pharmaceutical sales division, Airmed Biopharma Limited, ("Airmed" , a wholly owned Irish Company, has signed a non-exclusive distribution agreement with PanAm Global Logistics, Inc. ("PanAm" to market Lodonal(TM).

TNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal(TM) for Cancer and Receives First Sale in Africa
PR Newswire - Wed Jun 25, 7:35AM CDT
TNI BioTech, Inc. (OTC-TNIB) ("TNI BioTech" is pleased to announce that its pharmaceutical sales division, Airmed Biopharma Limited, ("Airmed" , a wholly owned Irish Company, has signed a non-exclusive distribution agreement with PanAm Global Logistics, Inc. ("PanAm" to market Lodonal(TM).

TNI BioTech, Inc. Cancels Proposed Reverse Split of its Common Stock
PR Newswire - Tue Jun 24, 7:00AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company" a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, announced today that its Board of Directors had passed a resolution cancelling the previously announced 9:10 reverse split of its common stock, as per the 14A Information Statement filed with the Securities and Exchange Commission on June 18, 2014, and accordingly will notify all appropriate regulatory authorities that the reverse split is withdrawn.

TNI BioTech, Inc. Files Schedule 14A and Announces Annual Meeting
PR Newswire - Wed Jun 18, 7:00AM CDT
TNI BioTech, Inc. (OTC: TNIB) ("TNI" or the "Company" announced today that it will hold its 2014 Annual Meeting ("Annual Meeting" of Stockholders on August 25, 2014. The Company has fixed the close of business on July 11, 2014 as the record date for determining shareholders entitled to notice of, and to vote at, the Annual Meeting. At the Annual Meeting, stockholders will be asked to elect eight directors to serve until the 2015 annual meeting of stockholders and until their successors have been elected and qualified.

TNI BioTech, Inc. Announces Further Agreement on Methionine-Enkephalin with Hubei Qianjiang Pharmaceutical Co., Ltd.
PR Newswire - Wed Mar 26, 9:00AM CDT
TNI BioTech, Inc. (OTC: TNIB), today announced that it has signed a 'Supplementary Cooperation Agreement (the "Agreement" on New Drug Methionine-Enkephalin' with Hubei Qianjiang Pharmaceutical Co., Ltd. (a Chinese listed company, hereinafter referred to as "Qianjiang" .

TNI BioTech, Inc. Granted Additional Patent for Methods for Inducing Sustained Immune Response of T-Cells
PR Newswire - Wed Mar 12, 9:00AM CDT
TNI BioTech, Inc. (OTC: TNIB), a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy through the acquisition and licensing of late development stage compounds, today announced the U.S. Patent and Trademark Office (USPTO) has granted a key patent for IRT-101 (MENK) for inducing sustained immune response of T-Cells.

The Brewer Group Announces Strategic Partnership with TNI BioTech, Inc.
PR Newswire - Fri Mar 07, 9:00AM CST
The Brewer Group, Inc. ("TBG" a global investment advisory firm, today announced a new strategic partnership with TNI BioTech, Inc. ("TNIB" (OTCQB: TNIB), a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Through a variety of business development strategies including exclusive access to its extensive global reach, TBG will provide tailored services including investment banking advisory as well as government, investor relations and marketing support to TNIB in an effort to offer affordable treatment technologies to those in need for as low as $1.00 USD per day in numerous markets throughout the world.

TNI BioTech, Inc. Forms New Subsidiary, Cytocom Inc., to develop LDN and MENK
PR Newswire - Thu Mar 06, 9:00AM CST
TNI BioTech, Inc. (OTC: TNIB) announced today that it has formed a new subsidiary, Cytocom, Inc., for the purpose of developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK).

TNI BIOTECH Announces SEC Clearance Of Form 10 Registration Statement And Clears Way To Upgrade To A Higher Exchange
PR Newswire - Tue Feb 11, 2:30PM CST
TNI BioTech Inc., (OTCQB:TNIB) a biotechnology company pioneering the development ofinnovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, today announced that it received notification from the U.S. Securities and Exchange Commission ("SEC" that the SEC has completed its review of the Company's Form 10 registration statement, effectively clearing all comments from the SEC.
GPI: 69.65 (+0.10)

TNI BioTech, Inc: Clarification of Press Release Pursuant to Form 8-K
ACCESSWIRE - Fri Sep 13, 11:34AM CDT
BETHESDA, MD, September 13, 2013 - (ACCESSWIRE) - On September 11, 2013 a press release entitled TNI BioTech, Inc. (OTCQB: TNIB) Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants was circulated. It incorrectly stated that the company "received a capital investment of $1,360,625.00 from the conversion existing warrants by our shareholders. The Company believes that other warrant holders will convert and provide the company with additional capital between $250,000 to $500,000 in the coming month." The correct statement, as illustrated by the company's 8-K filed on September 12, 2013 should read:




Scroll down for more posts ▼

Top 10 Most Recent News Articles

BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 75

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
Africa Tech Awards Put Infrastructure Back in Focus

Updated Category News Views 97

Twelve trophies in Cape Town tell a more useful story than most glossy technology forecasts ever manage to. The Africa Tech Festival Awards 2026, announced on November 19 during the event's 29th annual gathering, cut across connectivity, telecoms, AI, cybersecurity, data centres, cloud, fintech, startups and enterprise transformation. That breadth matters. Africa's...

Continue Reading
NEWWAVE Turns 15 and Chases a Bigger Tech Partner Role

Updated Category News Views 48

Fifteen years is about when an outsourced engineering shop has to prove it can be more than extra hands on a keyboard. NEWWAVE’s new identity and “Trusted Technology Partner” positioning are an attempt to make that jump: from carrying out software work to helping clients decide what work ought to be done, then sticking around after launch. It is a sensible ambition,...

Continue Reading
Securitize Tests the IPO Clock With Anthropic Tokens

Updated Category News Views 93

Anthropic did not even get a full trading day to itself before the tokenization crowd arrived. Securitize says Anthropic stock became available through Securitize Stocks on Solana on the company’s first day as a public company, a loud little signal that the old IPO playbook is being prodded from the edges. For investors, this is not merely another crypto-flavored...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 148

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 78

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 53

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 172

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 134

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 91

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Trends: The Effects of Inflation on Stock Futures

Updated Category News Views 87

Understanding Stock Market Movements Amid Inflation The stock market is always changing, and the way inflation data interacts with labor statistics often shapes its future direction. Recently, U.S. stock futures saw a slight uptick as investors digested fresh figures, weighing how these will influence upcoming decisions regarding interest rate cuts. Current Market...

Continue Reading
SMBC Nikko America Achieves Primary Dealer Status with Fed

Updated Category News Views 557

SMBC Nikko America Achieves Primary Dealer Designation SMBC Nikko Securities America, Inc., commonly referred to as SMBC Nikko America, has recently been honored with the designation of primary dealer by the Federal Reserve Bank of New York. This prestigious status is not only a recognition of the firm’s robust capabilities but also signals significant opportunities for...

Continue Reading
USD and Global Currency Trends Amid Upcoming Economic Events

Updated Category News Views 272

Currency Market Insights for the Upcoming Week As economic indicators and central bank policies loom large, the focus shifts to the financial markets where currencies react to evolving data. The US dollar has shown resilience recently, making a notable comeback. This rebound is attributed to a combination of safe haven flows and exceptionally positive data releases. Fed...

Continue Reading
Transforming $100 into Wealth: American Tower's Success Story

Updated Category News Views 152

The Wealth Generated by American Tower's Growth American Tower (NYSE: AMT) has exhibited exceptional performance over the past two decades, consistently outshining the market with a remarkable annual return of 10.05%. As of now, this powerhouse company boasts a market capitalization of approximately $83 billion, signaling its robust position in the telecommunications...

Continue Reading
Calcea: The Future of Calcium with Plant-Based Solutions

Updated Category News Views 258

Revolutionizing Calcium Supplements with Calcea Calcium is recognized as the most abundant mineral in the human body, yet many of the supplements available today are derived from ground-up rocks – materials that aren't aligned with the nutritional needs of the human body. With consumers increasingly prioritizing cleaner and more effective supplements, the calcium market...

Continue Reading